GDF15 and psoriasis: The limitations of this study (small sample size, absence of a control group without psoriasis, different psoriasis activity of the patients, and the fact that half of them were taking systemic treatment for psoriasis) do not allow us to validate the use of GDF-15 as a marker of atherosclerosis in subclinical psoriasis patients.